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Abstract 
The plasma level of fibrinogen is associated with the risk of ischaemic heart disease (IHD) and the severity of 
atherosclerosis. It has been suggested that an increased plasma level of fibrinogen is a coronary risk indicator because 
it reflects the inflammatory condition of the vascular wall. An inflamed vascular wall may increase the production of 
the cytokines interleukin 6 (IL6), interleukin l/3 (ILl,@, and tumour necrosis factor c( (TNFcc), which have a major 
role in the regulation of synthesis in the liver of acute phase proteins, including fibrinogen. Smoking has also been 
reported to increase the levels of fibrinogen and C-reactive protein (CRP). This may indicate that smoking induces 
an inflammatory reaction, probably of the pulmonary bronchi and alveolae. Therefore, we anticipated that with both 
types of inflammation the levels of acute phase proteins and cytokines would be related. We have investigated the 
contribution of inflammation to the plasma levels of fibrinogen in 34 patients with severe coronary artery disease 
(CAD) and 30 healthy controls comparable for age and smoking habits. We did not find a parallel in the effects of 
smoking and ischaemic heart disease on the plasma levels of fibrinogen, CRP, IL6, ILlD and TNFc(. Cardiovascular 
disease had its most important effect on the plasma fibrinogen level, while smoking appeared to increase the CRP 
levels, while both CAD and smoking seemed to affect the IL6 levels. Our results indicate that both smoking and CAD 
induce an inflammatory condition but that the increase of plasma levels of different inflammatory markers is complex. 
Although the acute phase reaction is the main regulatory mechanism of fibrinogen, the increase of fibrinogen in our 
group of CAD patients could not be fully explained by increased inflammation. 
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1. Introduction 
An elevated plasma fibrinogen level has been 
identified as an independent risk indicator for 
ischaemic heart disease and the severity of 
atherosclerosis in healthy populations [ l-31. Al- 
though several possible mechanisms have been 
postulated [4-61, the underlying mechanism has 
not yet been elucidated. One of the hypotheses is 
that increased plasma fibrinogen level may be a 
risk indicator because the level of fibrinogen, an 
acute phase protein, reflects the inflammatory 
state of the vascular wall. This is based on the 
theory of Ross et al. [7] that advanced lesions of 
atherosclerosis result from an excessive inflamma- 
tory-fibroproliferative response to numerous 
different forms of insults. The resulting low grade 
inflammation of the vascular wall has even been 
suggested to be the main ‘mechanism’ of 
atherosclerosis [7]. 
The role of inflammation in cardiovascular dis- 
ease is. further supported by reports on associa- 
tions of the pathogenesis of coronary artery 
disease and leucocyte count [8,9], monocyte count 
[lo], cytokines in the atheroma [l 11, expression of 
granulocyte and monocyte receptors [12], and infl- 
ammatory infiltrates in the cardiac arteries [13]. 
An inflamed vascular wall in patients with coro- 
nary artery disease may increase the levels of the 
cytokines IL6, ILlj? and TNFa. This is relevant, 
because these cytokines regulate the synthesis of 
acute phase proteins in the liver [14]. Therefore, 
we may expect that not only the plasma levels of 
fibrinogen, but also those of other markers of 
inflammatory response, such as levels of the sensi- 
tive acute phase protein CRP and those of IL6, 
ILla and TNFa, will increase. 
Smoking increases the plasma levels of both 
fibrinogen [15-171 and CRP [18,19] in healthy 
individuals, which suggests that smoking induces 
an inflammatory reaction. This is probably a low 
grade inflammation of the pulmonary bronchi and 
alveolae [20], which may result in a general acute 
phase reaction with increased fibrinogen and CRP 
levels. It has even been suggested that smoking is 
a cardiovascular isk factor through its elevating 
effect on the plasma fibrinogen level [2]. 
There are indications that the effect of smoking 
on the plasma fibrinogen level is greater in healthy 
volunteers than in patients who already have an 
increased plasma fibrinogen level. In healthy male 
volunteers a mean increase of 12% has been re- 
ported [15,17,21-241, while in vascular disease 
patients the plasma fibrinogen levels were com- 
parable in the non-smoking and the smoking pa- 
tients [25] or only slightly higher in the smokers 
(6%, P < 0.0001) [26]. 
In this study we established the effects of infl- 
ammation on the fibrinogen increase induced by 
coronary artery disease and by smoking. 
2. Patients and methods 
2.1. Patients and controls 
Thirty-four patients (26 male, 8 female) with 
angina complaints and scheduled for percuta- 
neous coronary transluminal angioplasty (PTCA) 
were enrolled in this study. A detailed description 
of the characteristics of the patient group is given 
in [27]. Briefly: on the diagnostic coronary an- 
giogram only one target vessel was considered 
responsible for the complaints. The mean (1 S.D.) 
age was 54.2 (8.3) years. Fifteen patients had a 
history of myocardial infarction, 6 patients had 
undergone PTCA earlier and in 2 patients a coro- 
nary artery bypass graft (CABG) operation had 
been performed before their participation in the 
study. The severity of angina1 complaints was 
scored according to the New York Heart Associa- 
tion classification: eight patients were in Class II, 
17 patients were in Class III and 9 patients were 
in Class IV. The patients did not take any medica- 
tion known to influence fibrinogen levels. 
On coronary angiography, one vessel disease 
(VD) was documented in 29 patients, two VD in 4 
patients and three VD in 1 patient. The target 
vessel was the left descending artery (LAD) in 17 
patients, the left circumflex artery in 7 patients 
and the right coronary artery in 10 patients. 
Since the levels of inflammatory markers are 
associated with age [28] and smoking habits, a 
control group was composed with comparable age 
and smoking habits. Fifteen non-smoking and 15 
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smoking healthy male blood donors, older than 
45 years, who consecutively visited the Rotter- 
dam Red Cross Bloodbank were included in the 
control group. 
The study was conducted in accordance with 
the Helsinki Declaration: approval was given by 
the Medical Ethical Committee of the Erasmus 
University, Rotterdam and written consent was 
obtained from the patients. 
2.2. jZnoking 
If smoking was stopped within 1 month before 
blood sampling the participant was considered a 
smoker. The ex-smokers who had stopped smok- 
ing at least 6 months before blood sampling were 
considered non-smokers. No patients had 
stopped smoking between 1 and 6 months before 
the start of the study. Sixteen patients and 15 
controls were smokers. 
2.3. Blood sawrpling 
Blood was collected and anticoagulated with 
5.4 mM EDTA on melting ice. After centrifuga- 
tion at 2000 x g for 15 min, the plasma was 
collected and stored at - 80°C until use. 
2.4. Fibrinogen 
Fibrinogen is measured with an enzyme im- 
muno assay that uses the monoclonal antibody 
G8 (directed against the COOH-terminal part of 
the fibrinogen a-chain) as a catching antibody 
and peroxidase conjugated Y 18 (directed against 
the NH,-terminal part of the fibrinogen a-chain) 
as tagging antibody [29]. 
2.5. C-reactive protein 
C-reactive protein is measured with a sensitive 
enzyme immu:no assay that uses rabbit anti- 
human C.-reactive protein (Dako A/S, Glostrup, 
Denmark) as a catching and a tagging antibody. 
2.6. Cytokines 
IL6, ILla and TNFc( w’ere measured with en- 
zyme immuno assays according to the instruc- 
tions of the manufacturer (Medgenix, 
Amersfoort, the Netherlands). The lower detec- 
tion limit of the IL6 and ILlg assays was 3 
pg/ml. 
2.7. Statistical analysis 
The distribution of the variables under study 
was positively skewed. Logarithmic transforma- 
tion gave a normal distribution for fibrinogen, 
CRP and TNFa, but not for ILlp and IL6 and 
therefore non-parametric tests were used to study 
the single variables. To evaluate whether there 
were significant differences between levels of sin- 
gle variables in the different groups, Fisher’s 
least significant differences procedure was used: 
first a Kruskal Wallis test was performed and 
next two groups at a time were compared using 
a Mann-Whitney test to determine which differ- 
ences between groups were significant. 
Because the fibrinogen levels were normally 
distributed after a logarithmic transformation, 
the effect of smoking on fibrinogen in CAD pa- 
tients and healthy controls and the effect of 
coronary heart disease in non-smoking and 
smoking individuals were studied after adjusting 
the fibrinogen levels for CRP and IL6 in a multi- 
ple regression analysis. 
3. Results 
When the plasma levels of acute phase 
proteins in the patient group were compared 
with those in the control group, the fibrinogen 
levels in the patients appeared to be significantly 
higher than those in the healthy controls (Table 
1). No differences for CRP were found. When 
comparing the plasma levels of the individual 
cytokines, only significantly higher IL6 levels 
were observed and not significantly higher ILla 
or TNFa levels. 
The effect of coronary artery disease was then 
studied in the non-smokers and the smokers sepa- 
rately. In the non-smokers the difference in the 
plasma fibrinogen levels between the healthy vol- 
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Table 1 
Median (lo-90 percentile range) of acute phase markers in 
healthy controls and patients 
Controls Patients P 
Fibrinogen (g/l) 2.09 2.87 0.0002 
(1.55-2.78) (1.94-4.19) 
C-reactive protein 1.99 1.3 0.54 
(mail) (0.33-9.15) (0.47-8.18) 
Interleukin-6 (pg/ml) 3.0 3.0 0.02 
(3.0-3.0) (3.0-17.5) 
Interleukin-1j3 (pg/ml) 3.0 
(3.0- 11.9) ;3:0-7.3) 
0.40 
When the fibrinogen levels were adjusted for 
CRP and IL6 to remove the acute phase compo- 
nent, the values were still significantly higher in 
non-smoking patients than in non-smoking con- 
trols (P < 0.001) and in smoking patients when 
compared with smoking controls (P = 0.03). This 
suggests that the effect of CAD on the plasma 
fibrinogen levels is regulated, as least partly, by a 
mechanism other than that which regulates the 
inflammatory markers CRP, IL6, ILl/? and 
TNFa. 
Tumour necrosis 8.8 8.7 0.96 
factor-a @g/ml) (3.9-24.5) (3.5-29.3) 
P gives the significance between the control and patient group 
as found using the Mann-Whitney test. 
unteers and the patient group was more pro- 
nounced than in the smokers (+ 0.94 g/l (49%, 
P = 0.02) and + 0.57 g/l (25%, P = O.OOS), respec- 
tively) (Table 2). The levels of CRP were low in 
non-smoking patients and controls and higher in 
smoking patients and controls. The effect of CAD 
on IL6 levels was significant in smokers only, and 
many had IL6 levels below the detection limit. In 
the Kruskal Wallis analysis no significant differ- 
ences between groups were found for ILla and 
TNFa. 
The effect of smoking was then studied in the 
patients and in the control group. The fibrinogen 
levels were similar in non-smoking and smoking 
patients, whereas there was a trend for an increase 
of 0.36 g/l in smokers (19O/,, P = 0.10) (Table 2, 
Fig. 1). Furthermore, it was observed that smok- 
ing gives a comparable increase of the CRP levels 
in CAD patients and in healthy controls ( + 2.1 
mg/l (254%) and + 3.0 mg/l (297%), respectively) 
(Table 2, Fig. 2). In many individuals in our study 
the levels of the IL6 and ILl/3 were below the 
detection limit of 3.0 pg/ml (Table 2, Fig. 3). Only 
in smoking CAD patients were the levels of IL6 
significantly increased. No effects on the ILlg and 
TNFa levels were found. 
When the fibrinogen levels were adjusted for 
CRP and IL6 smoking did not have an effect, 
Table 2 
Median (lo-90 percentile range) of acute phase markers in healthy controls and patients, considering their smoking status 
Controls Patients Statistics 
Non- Smokers Non- Smokers Kruskal A B C D 
smokers smokers Wallis 
Fibrinogen (g/l) Median 1.93 2.29 2.87 2.86 <O.OOl 0.10 0.25 0.02 0.008 
95% CI (1.48-2.71) (1.61-3.05) (1.68-3.60) (2.26-4.21) 
C-reactive protein (mg/l) Median 1 .OO 3.97 0.85 3.01 0.01 0.09 0.01 0.51 0.77 
95% CI (0.31-7.0) (0.61-10.7) (0.22-4.08) (0.68-17.3) 
Interleukin-6 (pg/ml) Median 3.0 
95% CI (3.0-3.0) (33:00_3.0) ;3:0-5.3) ;380-28.8) 
0.001 nd. 0.05 n.d. 0.007 
Interleukin- 1 jl (pg/ml) Median 3.0 3.0 3.0 3.0 0.22 
95% CI (3.0-3.0) (3.0-20.88) (3.0-6.2) (3.0-36.9) 
Tumour necrosis factor-a (pg/ml) Median 6.3 10.3 8.5 9.3 0.64 
95% CI (3.61-58.8) (4.9-24.5) (1.6-29.3) (3.5-26.5) 
Significance levels in columns: A, between non-smoking and smoking controls; B, between non-smoking and smoking patients; C, 
between non-smoking controls and non-smoking patients; D, between smoking controls and smoking patients. nd., not determined 
(too many very low levels). 
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Fig. 1. Fibrinogen levels for non-smoking and smoking con- 
trols, and non-smoking and smoking patients. 
while the effect of CAD remained after adjusting 
(see above), s’uggesting that the inflammatory re- 
action induced by smoking affects the studied 
parameters in a similar way. 
4. Discussion 
The plasm,a level of fibrinogen is associated 
with the extent of atherosclerosis and is also 
related to the risk of CAD. Since it has been 
hypothesized that inflammation of the vascular 
wall underlies; the increased fibrinogen levels, we 
studied the relation between plasma fibrinogen 
levels and a selection of inflammatory markers, 
namely CRP, IL6, ILlg and TNFa, in patients 
C-reactive protein (ma/L) 
9% 10 . : :: . . : .: . I 
non-smokers smokers non-smokers smokers 
controls patients 
Fig. 2. C-reactive protein levels for non-smoking and smoking 
controls, and non-smoking and smoking patients. 
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Fig. 3. Interleukin-6 levels for non-smoking and smoking 
controls, and non-smoking and smoking patients. 
with severe CAD and in healthy volunteers. The 
patients had significantly higher levels of fibrino- 
gen and IL6 than controls, in accordance with 
that hypothesis. However, the levels of the very 
sensitive acute phase protein CRP did not differ 
between patients and healthy volunteers. 
Since it is known that the levels of the acute 
phase proteins are associated with smoking, the 
effect of CAD was analysed separately in non- 
smokers and in smokers. We found that smoking 
did not increase the fibrinogen levels in our CAD 
patients further, but had a small effect in healthy 
volunteers. Apparently, CAD is a major determi- 
nant for increased fibrinogen levels. This finding 
agrees with the results of the PLAT Study [25] 
and the ECAT Angina Pectoris Study [26] de- 
scribing a minor effect of smoking on the plasma 
fibrinogen levels of patients with vascular disease, 
and studies in healthy volunteers which reported a 
positive effect of smoking [3,15-181. 
The behaviour of CRP was different from that 
of fibrinogen, since levels were equally elevated by 
smoking in the controls and the patients. Acute 
phase proteins, especially CRP, react strongly to 
inflammatory reactions. In this study, we show 
that smoking is a strong determinant of the 
plasma fibrinogen levels, while the effect of CAD 
is negligible. 
The increase of the levels of the acute phase 
markers CRP and IL6 by smoking in controls and 
CAD patients supports the hypothesis of an in- 
creased inflammatory status in smokers. The syn- 
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thesis of fibrinogen and CRP in the liver is mainly 
regulated by IL6, ILl/3 and TNFcl [14]. However, 
in this study the levels of IL6 are higher in 
smoking than in non-smoking patients, but not in 
controls. Apparently, the inflammatory reaction 
caused by smoking is not sufficient o increase the 
levels of this cytokine. 
In the ECAT Angina Pectoris Study both 
fibrinogen and CRP levels were risk indicators for 
cardiovascular events, but when the inflammatory 
component was removed from the plasma fibrino- 
gen levels by adjusting them for CRP, fibrinogen 
was still an indicator for risk. This suggests that 
the level of fibrinogen is not merely an epiphe- 
nomenon of the inflammatory reaction. There- 
fore, we evaluated whether the acute phase 
reaction was the only regulatory mechanism that 
contributed to the observed increase in the levels 
of fibrinogen by adjusting the fibrinogen levels for 
CRP and IL6. The effect of smoking in controls 
was reduced, indicating that smoking indeed in- 
duces an inflammatory response. However, both 
in smokers and in non-smokers, a significant infl- 
uence of atherosclerosis on the fibrinogen levels 
still remained. This implies that the inflammatory 
markers that we studied have a complex be- 
haviour or that another mechanism may also be 
involved here, which may be at least partly ge- 
netic, as it has been reported that up to 51% of 
the fibrinogen level is genetically determined 
[30,31]. 
In summary, we have shown that (1) in patients 
with CAD, levels of fibrinogen and IL6 are in- 
creased, and not CRP when compared with con- 
trols; (2) CAD has a greater effect on fibrinogen 
levels than smoking; (3) smoking, but not CAD, 
affects the levels of CRP; and (4) the effect of 
CAD on the level of IL6 depends on smoking. 
Therefore, the increase of the plasma fibrinogen 
levels in patients with CAD cannot be fully ex- 
plained by an increased inflammatory status 
reflected by IL6 and CRP. 
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